COVID-19 Thrombosis Prevention Trials: Post-hospital Thromboprophylaxis
NCT ID: NCT04650087
Last Updated: 2025-02-25
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
1291 participants
INTERVENTIONAL
2021-02-15
2022-09-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical Illness
NCT00457002
Observational, Retrospective Study to Evaluate Coagulation Changes and the Influence of Antithrombin III Treatment in Patients With Severe COVID-19 Infection
NCT04651400
Safety and Efficacy of Therapeutic Anticoagulation on Clinical Outcomes in Hospitalized Patients With COVID-19
NCT04377997
Apixaban for PrOphyLaxis of thromboemboLic Outcomes in COVID-19
NCT04746339
Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism
NCT00633893
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The primary objective is to determine the most effective and safe antithrombotic strategy to prevent the composite outcome of symptomatic deep vein thrombosis, pulmonary embolism, other venous thromboembolism, ischemic stroke, myocardial infarction, other arterial thromboembolism, and all-cause mortality by 30 days following discharge from the hospital.
Biobanking of samples for future biomarker and mechanistic studies will be available for centers able to participate and collect samples from eligible participants. Samples will be collected at the time of enrollment and after the completion of 30 days of therapy
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Apixaban
Drug: Apixaban 2.5 MG Participants will be given study medication at the time of discharge from the hospital. Participants will take Apixaban 2.5 MG twice a day, once in the morning and once in the evening, for 30 days. Participants will be contacted (electronic or telephone) 2 days after starting the study medication and contact will continue up to day 90 after starting study treatment. Follow up will be through electronic and/or telephone contact depending on the participant's preference, compliance, and medication adherence. Participants will be queried for any clinically relevant endpoints, especially major bleeding or a need to seek healthcare attention for any reason. Follow-up will occur from the time of discharge and through the 30 day study period, with contacts 2 days, 10 days, 20 days, and 30 days after discharge. Two additional study contacts will take place 45 days and 90 days after discharge.
Apixaban 2.5 MG
Participants will take Apixaban 2.5 MG twice a day, once in the morning and once in the evening for 30 days. Participants will be contacted (electronic or telephone) 2 days after starting the study medication and will continue up to day 90 after starting study treatment. Followup will occur from the time of discharge through the 30 day study period with contacts at 2 days, 10 days, 20 days and 30 days after discharge. Two additional study contacts will take place 45 days and 90 days after discharge.
Placebo
Drug: Placebo Participants will be given study medication at the time of discharge from the hospital. Participants will take the Placebo twice a day, once in the morning and once in the evening, for 30 days. Participants will be contacted (electronic or telephone) 2 days after starting the study medication and contact will continue up to day 90 after starting study treatment. Follow up will be through electronic and/or telephone contact depending on the participant's preference, compliance, and medication adherence. Participants will be queried for any clinically relevant endpoints, especially major bleeding or a need to seek healthcare attention for any reason. Follow-up will occur from the time of discharge and through the 30 day study period, with contacts 2 days, 10 days, 20 days, and 30 days after discharge. Two additional study contacts will take place 45 days and 90 days after discharge.
Placebo
Participants will take placebo twice a day, once in the morning and once in the evening for 30 days. Participants will be contacted (electronic or telephone) 2 days after starting the study medication and will continue up to day 90 after starting study treatment. Followup will occur from the time of discharge through the 30 day study period with contacts at 2 days, 10 days, 20 days and 30 days after discharge. Two additional study contacts will take place 45 days and 90 days after discharge.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Apixaban 2.5 MG
Participants will take Apixaban 2.5 MG twice a day, once in the morning and once in the evening for 30 days. Participants will be contacted (electronic or telephone) 2 days after starting the study medication and will continue up to day 90 after starting study treatment. Followup will occur from the time of discharge through the 30 day study period with contacts at 2 days, 10 days, 20 days and 30 days after discharge. Two additional study contacts will take place 45 days and 90 days after discharge.
Placebo
Participants will take placebo twice a day, once in the morning and once in the evening for 30 days. Participants will be contacted (electronic or telephone) 2 days after starting the study medication and will continue up to day 90 after starting study treatment. Followup will occur from the time of discharge through the 30 day study period with contacts at 2 days, 10 days, 20 days and 30 days after discharge. Two additional study contacts will take place 45 days and 90 days after discharge.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* PCR-positive COVID-19 infection
* Hospitalized for two or more days
Exclusion Criteria
* Contraindication to antithrombotic therapy (e.g., known bleeding within the last 30 days requiring emergency room presentation or hospitalization; major surgery within 14 days; ischemic stroke, intracranial bleed or neurosurgery within 3 months.
* Platelet count \< 50,000/mcL
* Hemoglobin \<8 gm/dL
* Renal insufficiency (eGFR \< 30 mL/min/1.73 m2)
* Pregnancy
* Prison inmate
* Life expectancy less than 90 days
* Unwilling or unable to provide informed consent/unwilling or unable to complete the study protocol
* Dual antiplatelet therapy that cannot be discontinued
* Concomitant need for strong inducers/inhibitors of p-gp or CYP3A4
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Thomas L. Ortel
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Thomas L. Ortel
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tracy Wang, MD
Role: PRINCIPAL_INVESTIGATOR
Duke University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Valleywise Health Medical Center
Phoenix, Arizona, United States
Dignity Health-St Josephs
Phoenix, Arizona, United States
Central Arkansas Veterans Health Care System
Little Rock, Arkansas, United States
University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States
Stanford University School of Medicine
Palo Alto, California, United States
UCSF at Zuckerberg San Francisco General Hospital
San Francisco, California, United States
New Ananda Medical and Urgent Care, Inc.
South El Monte, California, United States
Mazur and Statner MD PC
Thousand Oaks, California, United States
Torrance Medical Center
Torrance, California, United States
Centura Health Porter Adventist Hospital
Denver, Colorado, United States
Saint Anthony Hospital
Lakewood, Colorado, United States
St. Anthony North Health Campus
Westminster, Colorado, United States
Baycare Hospital
Clearwater, Florida, United States
Florida Heart Center
Ft. Pierce, Florida, United States
University of Florida
Gainesville, Florida, United States
Mount Sinai Medical Center
Miami Beach, Florida, United States
Tallahassee Memorial HealthCare
Tallahassee, Florida, United States
James A. Haley Veteran's Hospital
Tampa, Florida, United States
BayCare Hospital- Winter Haven
Winter Haven, Florida, United States
Emory University
Atlanta, Georgia, United States
Medical College of Georgia/Augusta University
Augusta, Georgia, United States
Savannah Health Services, LLC DBA Memorial Health University Medical Center
Savannah, Georgia, United States
Queens Medical Center
Honolulu, Hawaii, United States
Hawaii Pacific Health
Honolulu, Hawaii, United States
Snake River Research, PLLC
Idaho Falls, Idaho, United States
University of Illinois at Chicago
Chicago, Illinois, United States
Cook County Health
Chicago, Illinois, United States
Rush University Medical Center
Chicago, Illinois, United States
The University of Chicago Medicine
Chicago, Illinois, United States
OSF Little Company of Mary
Evergreen Park, Illinois, United States
Loyola University Medical Center
Maywood, Illinois, United States
Indiana University Health Bloomington Hospital
Bloomington, Indiana, United States
Lutheran Medical Group
Fort Wayne, Indiana, United States
Indiana University Health Methodist Hospital
Indianapolis, Indiana, United States
Franciscan Health Michigan City
Michigan City, Indiana, United States
Reid Physician Associates
Richmond, Indiana, United States
Baptist Health Lexington
Lexington, Kentucky, United States
University Medical Center New Orleans
New Orleans, Louisiana, United States
Ochsner Clinic Foundation-Baton Rouge
New Orleans, Louisiana, United States
Ochsner Clinic Foundation
New Orleans, Louisiana, United States
Willis-Knighton Physician Network/Tri-State Medical Clinic
Shreveport, Louisiana, United States
Maine Medical Center/Maine Medical Partners Adult Hospital Medicine
Portland, Maine, United States
Pen Bay Medical Center
Rockport, Maine, United States
Anne Arundel Medical Center
Annapolis, Maryland, United States
Lifebridge (Sinai Hospital of Baltimore)
Baltimore, Maryland, United States
Adventist HealthCare Shady Grove Medical Center
Rockville, Maryland, United States
Boston University
Boston, Massachusetts, United States
Lahey Hospital and Medical Center
Burlington, Massachusetts, United States
Baystate Medical center
Springfield, Massachusetts, United States
Bay Regional Medical Center d/b/a/ McLaren Bay Region
Bay City, Michigan, United States
Henry Ford Hospital
Detroit, Michigan, United States
Western Michigan University
Kalamazoo, Michigan, United States
MidMichigan Medical Center
Midland, Michigan, United States
McLaren Macomb
Mount Clemens, Michigan, United States
Minneapolis VA Health Care System
Minneapolis, Minnesota, United States
University of Mississippi Medical Center
Jackson, Mississippi, United States
Truman Medical Center
Kansas City, Missouri, United States
Barnes-Jewish Hospital
St Louis, Missouri, United States
St Louis University
St Louis, Missouri, United States
Mercury Street Medical Group
Butte, Montana, United States
CHI St Elizabeth Hospital
Lincoln, Nebraska, United States
Renown Health
Reno, Nevada, United States
Dartmouth Hichcock Medical Center
Lebanon, New Hampshire, United States
AtlantiCare Regional Medical Center
Atlantic City, New Jersey, United States
Hope Tower at Jersey Shore University Medical Center
Neptune City, New Jersey, United States
Newark Beth Israel Medical Center
Newark, New Jersey, United States
Capital Health System, Inc.
Trenton, New Jersey, United States
Christus St. Vincent Regional Medical Center
Santa Fe, New Mexico, United States
NYU Langone Hospital-Brooklyn
Brooklyn, New York, United States
Coney Island Hospital
Brooklyn, New York, United States
Buffalo General Medical Center
Buffalo, New York, United States
Mercy Hospital Buffalo
Buffalo, New York, United States
Jamaica Hospital Medical Center
Jamaica, New York, United States
New York University Langone Health
New York, New York, United States
Stony Brook University Hospital
Stony Brook, New York, United States
Montefiore Medical Center
The Bronx, New York, United States
Westchester Medical Center
Valhalla, New York, United States
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States
Duke Medical Center
Durham, North Carolina, United States
East Carolina University/Vidant Health
Greenville, North Carolina, United States
Wake Med Hospital
Raleigh, North Carolina, United States
Wake Forest Baptist Medical Center
Winston-Salem, North Carolina, United States
Summa Health
Akron, Ohio, United States
University of Cincinnati
Cincinnati, Ohio, United States
Cleveland Clinic Foundation
Cleveland, Ohio, United States
Ohio State University
Columbus, Ohio, United States
Kettering Medical Center
Kettering, Ohio, United States
Ascension St. John Bartlesville
Tulsa, Oklahoma, United States
Ascension St. John Tulsa
Tulsa, Oklahoma, United States
Oregon Health and Science University
Portland, Oregon, United States
St. Luke's University Health Network
Easton, Pennsylvania, United States
Conemaugh Memorial Medical Center
Johnstown, Pennsylvania, United States
Temple University Hospital
Philadelphia, Pennsylvania, United States
University of Pittsburgh
Pittsburgh, Pennsylvania, United States
Tower Health Medical Group
West Reading, Pennsylvania, United States
Rhode Island Hospital
Providence, Rhode Island, United States
The Miriam Hospital
Providence, Rhode Island, United States
Monument Health Clinical Research
Rapid City, South Dakota, United States
Erlanger Health System
Chattanooga, Tennessee, United States
Vanderbilt University Medical Center
Nashville, Tennessee, United States
Christus St. Elizabeth Hospital
Beaumont, Texas, United States
Baylor Scott and White Medical Center- College Station
College Station, Texas, United States
University of Texas Southwestern Medical Center
Dallas, Texas, United States
Texas Health Harris Methodist
Fort Worth, Texas, United States
University of Texas- Houston, LBJ Hospital
Houston, Texas, United States
UT Houston MHH-SW
Houston, Texas, United States
UTHouston
Houston, Texas, United States
Texas Health Frisco
Plano, Texas, United States
Baylor Scott and White-Round Rock
Round Rock, Texas, United States
Baylor Scott and White-Temple
Temple, Texas, United States
The Woodlands Center For Respiratory & Sleep Research
The Woodlands, Texas, United States
CHRISTUS Trinity Clinic Pulmonary Medicine
Tyler, Texas, United States
The University of Texas Health Science Center at Tyler
Tyler, Texas, United States
UT Health East Texas (Tyler)
Tyler, Texas, United States
UT Rio Grande Valley
Weslaco, Texas, United States
MultiCare Institute for Research & Innovation
Puyallup, Washington, United States
UW Medicine Valley Medical Center
Renton, Washington, United States
Virginia Mason Medical Center
Seattle, Washington, United States
CAMC Clinical Trials Center
Charleston, West Virginia, United States
West Virginia University Hospital
Morgantown, West Virginia, United States
Blood Center of Wisconsin
Milwaukee, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Santos BC, Flumignan RL, Civile VT, Atallah AN, Nakano LC. Prophylactic anticoagulants for non-hospitalised people with COVID-19. Cochrane Database Syst Rev. 2023 Aug 16;8(8):CD015102. doi: 10.1002/14651858.CD015102.pub2.
Wang TY, Wahed AS, Morris A, Kreuziger LB, Quigley JG, Lamas GA, Weissman AJ, Lopez-Sendon J, Knudson MM, Siegal DM, Kasthuri RS, Alexander AJ, Wahid L, Atassi B, Miller PJ, Lawson JW, Patel B, Krishnan JA, Shapiro NL, Martin DE, Kindzelski AL, Leifer ES, Joo J, Lyu L, Pennella A, Everett BM, Geraci MW, Anstrom KJ, Ortel TL; ACTIV-4C Study Group. Effect of Thromboprophylaxis on Clinical Outcomes After COVID-19 Hospitalization. Ann Intern Med. 2023 Apr;176(4):515-523. doi: 10.7326/M22-3350. Epub 2023 Mar 21.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Pro00107078
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.